Latest

3 stories

Hide weekly roundups

Tuesday, August 11

Quarterly updateAutolus Therapeutics plc

Autolus posts $45.7 million in AUCATZYL revenue, raises 2026 guidance

Autolus reported second-quarter net product revenue growth of 119% year over year and increased full-year revenue guidance to $140-150 million, while advancing obe-cel trials in lupus nephritis, pediatric ALL.

SEC filing

Monday, August 3

PartnershipAutolus Therapeutics plc

Autolus enters $250 million notes facility with Perceptive Credit Holdings

Autolus drew a $75 million first tranche on July 30, 2026, with up to $175 million more available across three additional tranches tied to revenue milestones.

SEC filing

FinancingAutolus Therapeutics plc

Autolus reports Q2 AUCATZYL revenue, raises 2026 guidance, secures $250M facility

The company posted preliminary Q2 net product revenue and lined up a five-year credit facility with Perceptive Advisors as it raised full-year sales guidance.

SEC filing